The recent launch of generic versions of Xeljanz is a striking example of the savings that can be generated when competitive drugs enter the market.

After multiple legal attempts by the brand-name manufacturer to prevent generic entry, the first Xeljanz generics launched in early June. Xeljanz (tofacitinib) is an oral JAK inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and other inflammatory conditions.

This development marks the first generic JAK inhibitor to enter the market, creating an important cost-saving option for patients and plan sponsors. It joins a growing list of lower-cost alternatives for these conditions, including biosimilars for Humira® and Stelara®.

While generic introductions typically produce savings over time, the Xeljanz example demonstrates how quickly competition can change drug pricing.

Pricing Fell from $78,000 to $2,000 in Weeks

The market has responded rapidly to the introduction of generic Xeljanz.

Low-Dose Extended-Release

For the low-dose extended-release formulation, nine manufacturers have already launched generic products, with at least three more expected to enter the market in the second half of 2026. This level of competition has reduced the annual wholesale acquisition cost (WAC) from around $78,000 to $2,000. That’s a reduction of more than 97%.

Immediate-Release

The immediate-release products launched with eight manufacturers in June, with another 10 expected to launch in 2026. That competition has reduced annual WAC from $55,000 to $600.

High-Dose Extended Release

The higher-dose extended-release product has seen a slower generic rollout because the first generic manufacturer received 180 days of market exclusivity. However, that delay can be overcome using two of the available low-dose products.

 

Align Your Pharmacy Benefits Plan Now

To realize savings from a generic drug launch, employer health plans must ensure their pharmacy benefits are properly aligned. This includes reviewing the plan’s formulary to make the generic readily accessible to members and, when clinically appropriate, removing the brand-name product from preferred formulary status. If a PBM continues to favor the brand after a lower-cost generic becomes available, plan sponsors may miss significant savings opportunities.

This is particularly important with high-cost specialty medications where even a single drug can have a significant impact on overall drug spend.

The Xeljanz launch demonstrates why ongoing pharmacy benefits management is so essential. Drug approvals, generic launches, biosimilar availability and market competition are continually reshaping the cost landscape. When considering plan changes, employers should evaluate these developments alongside utilization trends, net costs after rebates and discounts, and PBM contract terms and guarantees.

 

The Bottom Line

The introduction of generic Xeljanz is a powerful reminder that changes in the drug market and pharmacy benefits can happen quickly. A drug that once cost tens of thousands of dollars annually can become far less expensive almost overnight when competition enters the market.

Capturing savings requires employers and pharmacy benefits consultants to continually evaluate the market and make timely formulary and benefit decisions.